All Stories

  1. Multimodal neuroimaging elucidates the posterior-to-anterior gradient of nigrostriatal degeneration in Parkinson’s disease
  2. Targeting the crosstalk between Alzheimer’s disease and gastrointestinal cancers
  3. Transcranial pulse stimulation modulates spectral signatures of Alzheimer’s disease in the 3×Tg-AD mouse model
  4. White matter 18F-florbetapir retention predicts cognitive decline and treatment response in Alzheimer’s disease
  5. Divergent scalp-to-region distance alteration patterns in autism spectrum disorders, Parkinson’s disease and Alzheimer’s disease
  6. Design, synthesis, and characterization of F-18 sigma-1 receptor radiotracers for Alzheimer disease
  7. In vivo measures of glutamate and the excitation/inhibition imbalance in brain disorders
  8. Multimodal imaging-guided precise neuromodulation for Alzheimer’s disease
  9. Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications
  10. [18F]florbetapir PET for early detection of amyloidosis in patients with hereditary transthyretin amyloidosis polyneuropathy
  11. Editorial: Update on the diagnosis, treatment, and research of cerebral cavernous malformations
  12. Integration of functional magnetic resonance imaging and artificial intelligence in Alzheimer’s disease
  13. Brain Extracellular Space: From an Overlooked Dimension to Catalyst of a Novel Neuroscience Paradigm
  14. Isoliquiritigenin Attenuates Tau-Associated Neuroinflammation by Inhibiting NLRP3 Inflammasome Activation in Alzheimer’s Disease
  15. Enhanced ex vivo 3D whole-brain mapping and automated analysis of Parkinson’s disease pathologies in mice
  16. Noninvasive imaging of amyloid‐beta and tau in rodent and nonhuman primate models
  17. Plasma growth-associated protein 43 correlates with synaptic loss in Alzheimer’s disease
  18. Investigating the Association Between P2Y12 Receptor, SV2A, and Tau Expression in Postmortem AD and Control Brains Using In Vitro Autoradiography
  19. Multi‐scale imaging of α‐synuclein, dopamingeric neurodegeneration and microstructural changes in α‐synuclein PFF mouse model of Parkinson's disease
  20. Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer’s disease brain are associated with Aβ, tau pathologies and synaptic loss
  21. Transcranial pulse stimulation modulates neuronal activity and functional network dynamics
  22. Chemerin-CMKLR1 differentially mediated OGD/R-induced mitochondrial dysfunction, oxidative stress, and autophagy in microglia and neurons
  23. Discerning Amyloid-β and Tau Pathologies with Learning-Based Quantum Sensing
  24. Non-invasive large-scale imaging of concurrent neuronal, astrocytic, and hemodynamic activity with hybrid multiplexed fluorescence and magnetic resonance imaging (HyFMRI)
  25. Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer’s disease: associations with Aβ, tau, synaptic proteins and APOE ε4
  26. Spinal cord imaging in preclinical research
  27. Isoliquiritigenin attenuated cognitive impairment, cerebral tau phosphorylation and oxidative stress in a streptozotocin-induced mouse model of Alzheimer's disease
  28. Head-to-head comparison of [18F]florbetapir and [18F]FDG PET for the early detection of amyloidosis in systemic amyloidosis and plasma cell dyscrasias
  29. Synthesis and in vivo biological characterization of six carbon-11 sigma-1 receptor radiotracers in rodent and nonhuman primate
  30. Chemerin-CMKLR1 mediated OGD/R induced Mitochondrial Dysfunction, Oxidative Stress, and Autophagy differentially in Microglia and Neurons
  31. Synaptic loss pattern is constrained by brain connectome and modulated by phosphorylated tau in Alzheimer’s disease
  32. Prediction of longitudinal synaptic loss in Alzheimer's disease using tau PET and plasma biomarkers
  33. Imaging alpha-synuclein pathology in Parkinson’s disease
  34. Tau pathology is associated with postsynaptic metabotropic glutamate receptor 5 (mGluR5) in early Alzheimer's disease in a sex‐specific manner
  35. Multimodal imaging of murine cerebrovascular dynamics induced by transcranial pulse stimulation
  36. Biomarkers for synaptic dysfunction in Alzheimer’s disease
  37. Applications of Positron Emission Tomography (PET) in Preclinical Research
  38. Distinguishing Alzheimer’s Pathologies with Machine Learning-Aided Quantum Sensing
  39. Hybrid fluorescence and magnetic resonance imaging (HyFMRI) platform for functional neuroimaging
  40. Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models
  41. Imaging of amyloid, tau and synaptic dysfunction in the brains of type 2 diabetic rats ‐ a multitracer PET study
  42. mTOR inhibition alleviated tau phosphorylation-induced mitochondrial impairment, oxidative stress, and cognitive impairment
  43. Spiral volumetric optoacoustic tomography of reduced oxygen saturation in the spinal cord of M83 mouse model of Parkinson’s disease
  44. Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer’s disease mice by regulating oxidative stress and tau hyperphosphorylation
  45. Effect of APOE ɛ4 Status on Brain Amyloid‐β and Cognitive Function in Amnestic and Nonamnestic Mild Cognitive Impairment: A [18F] Florbetapir PET‐CT Study
  46. Visualizing alpha‐synuclein and iron deposition in M83 mouse model of Parkinson's disease in vivo
  47. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, tau and alpha-synuclein
  48. Gastrodin ameliorates synaptic impairment, mitochondrial dysfunction and oxidative stress in N2a/APP cells
  49. In vivo reactive astrocyte imaging using [18F]SMBT-1 in tauopathy and familial Alzheimer's disease mouse models: A multi-tracer study
  50. Increased Cerebral Level of P2X7R in a Tauopathy Mouse Model by PET Using [18F]GSK1482160
  51. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment
  52. Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease
  53. Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET
  54. NRF2 Deficiency Promotes Ferroptosis of Astrocytes Mediated by Oxidative Stress in Alzheimer’s Disease
  55. Increased regional P2X7R uptake detected by [18F]GSK1482160 PET in a tauopathy mouse model
  56. Advances in non-invasive imaging of proteinopathies in animal models of neurodegenerative diseases
  57. Noninvasive Visualization of Amyloid-Beta Deposits in Alzheimer’s Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent
  58. Probing Chemical Complexity of Amyloid Plaques in Alzheimer’s Disease Mice using Hyperspectral Raman Imaging
  59. Relationship between reactive astrocytes, by [18F]SMBT-1 imaging, with amyloid-beta, tau, glucose metabolism, and microgliosis in mouse models of Alzheimer’s disease
  60. Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion
  61. Inorganic phosphate exporter heterozygosity in mice leads to brain vascular calcification, microangiopathy, and microgliosis
  62. Collection on molecular imaging in neurodegeneration
  63. Visualizing alpha-synuclein and iron deposition in M83 mouse model of Parkinson’s diseasein vivo
  64. Deep optoacoustic localization microangiography of ischemic stroke in mice
  65. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma
  66. Aquaporin 4 is differentially increased and dislocated in association with tau and amyloid-beta
  67. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, 4-repeat/full-length tau and alpha-synuclein
  68. NRF2 deficiency promotes ferroptosis of astrocytes mediated by oxidative stress in Alzheimer’s disease
  69. Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly
  70. Monitoring mouse brain perfusion with hybrid magnetic resonance optoacoustic tomography
  71. PET imaging in animal models of Parkinson’s disease
  72. Coregistered transcranial optoacoustic and magnetic resonance angiography of the human brain
  73. Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly
  74. Gastrodin ameliorates synaptic impairment, reestablishes mitochondrial membrane potential and reduces oxidative stress in N2a/APP cells through ERK1/2 and GSK-3β pathways
  75. ChemR23 signaling ameliorates cognitive impairments in diabetic mice via dampening oxidative stress and NLRP3 inflammasome activation
  76. Simultaneous Functional Magnetic Resonance and Optoacoustic Imaging of Brain‐Wide Sensory Responses in Mice
  77. Hybrid magnetic resonance and optoacoustic tomography (MROT) for preclinical neuroimaging
  78. Automatic image registration of optoacoustic tomography and magnetic resonance imaging based on deep learning
  79. Evaluation of cannabinoid type 2 receptor expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease
  80. Quercetin reduces APP expression, oxidative stress and mitochondrial dysfunction in the N2a/APPswe cells via ERK1/2 and AKT pathways
  81. Deep learning facilitates fully automated brain image registration of optoacoustic tomography and magnetic resonance imaging
  82. Sensitive ultrawideband transparent PVDF-ITO ultrasound detector for optoacoustic microscopy
  83. Multimodal Noninvasive Functional Neurophotonic Imaging of Murine Brain‐Wide Sensory Responses (Adv. Sci. 24/2022)
  84. Evaluation of CB2R expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease
  85. Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice
  86. Editorial: Translational imaging in neurodegenerative proteinopathies
  87. Multimodal Noninvasive Functional Neurophotonic Imaging of Murine Brain‐Wide Sensory Responses
  88. Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography
  89. Noninvasive optoacoustic imaging of the human brain validated with magnetic resonance angiography
  90. Structural MRI Reveals Cervical Spinal Cord Atrophy in the P301L Mouse Model of Tauopathy: Gender and Transgene-Dosing Effects
  91. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
  92. Recent Technical Advances in Accelerating the Clinical Translation of Small Animal Brain Imaging: Hybrid Imaging, Deep Learning, and Transcriptomics
  93. Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography
  94. Emodin Protects SH-SY5Y Cells Against Zinc-Induced Synaptic Impairment and Oxidative Stress Through the ERK1/2 Pathway
  95. Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways
  96. The Impact of Uremic Toxins on Alzheimer's Disease
  97. Magnetic Resonance Imaging in Tauopathy Animal Models
  98. Positron Emission Tomography in Animal Models of Tauopathies
  99. Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
  100. Evaluation of Transcranial Optoacoustic Imaging of a Human Brain Phantom
  101. High‐resolution non‐invasive whole brain imaging of tauopathy in a tauopathy mouse model
  102. Arterial spin labeling demonstrates preserved regional cerebral blood flow in the P301L mouse model of tauopathy
  103. Magnetic Resonance Imaging in Animal Models of Alzheimer’s Disease Amyloidosis
  104. Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
  105. In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI
  106. Multimodal Contrast Agents for Optoacoustic Brain Imaging in Small Animals
  107. PET Imaging of Neuroinflammation in Alzheimer’s Disease
  108. In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice
  109. The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment
  110. Real-World Outcomes of Revascularization Strategies in Patients With Left Ventricular Dysfunction and Three-Vessel Coronary Disease Stratified by Mitral Regurgitation
  111. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
  112. In vivo localization optoacoustic tomography (LOT) with particles smaller than red blood cells
  113. Multi-scale optoacoustic molecular imaging of brain diseases
  114. Non-invasive optoacoustic imaging of tau in P301L mice
  115. Transcranial detection of amyloid‐beta at single plaque resolution in vivo with large‐field multifocal illumination fluorescence microscopy
  116. Transcranial detection of tauopathy in vivo in P301L mice with high‐resolution large‐field multifocal illumination fluorescence microscopy
  117. Volumetric multispectral optoacoustic tomography of beta‐amyloid deposits in whole mouse brain
  118. Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy
  119. SWI and phase imaging reveal intracranial calcifications in the P301L mouse model of human tauopathy
  120. Whole brain optoacoustic tomography reveals strain-specific regional beta-amyloid densities in Alzheimer’s disease amyloidosis models
  121. Transcranial in vivo detection of amyloid-beta at single plaque resolution with large-field multifocal illumination fluorescence microscopy
  122. Diffusion Tensor Imaging Reveals Whole-Brain Microstructural Changes in the P301L Mouse Model of Tauopathy
  123. Tau deposition is associated with imaging patterns of tissue calcification in the P301L mouse model of human tauopathy
  124. Simulation of fluorescence molecular tomography using a registered digital mouse atlas
  125. Automated registration of magnetic resonance imaging and optoacoustic tomography data for experimental studies
  126. International Photoacoustic Standardisation Consortium (IPASC): overview (Conference Presentation)
  127. fMRI Reveals Mitigation of Cerebrovascular Dysfunction by Bradykinin Receptors 1 and 2 Inhibitor Noscapine in a Mouse Model of Cerebral Amyloidosis
  128. Automated registration for optoacoustic tomography and MRI
  129. BRADYKININ ANTAGONIST NOSCAPINE MITIGATES CEREBROVASCULAR DYSFUNCTION IN THE ARCAβ MOUSE MODEL OF ALZHEIMER’S DISEASE
  130. EVALUATION OF CANNABINOID RECEPTOR 2 PET IMAGING TRACERS IN ALZHEIMER’S DISEASE BRAIN
  131. IN VIVO OPTOACOUSTIC TOMOGRAPHY OF BRAIN AMYLOID DEPOSITS IN AN ARCAβ MOUSE MODEL OF ALZHEIMER’S DISEASE
  132. Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system
  133. Cortical hypoperfusion and reduced cerebral metabolic rate of oxygen in the arcAβ mouse model of Alzheimer’s disease
  134. Optimization of GERD Therapeutic Regimen Based on ANN and Realization of MATLAB
  135. Noninvasive detection of acute cerebral hypoxia and subsequent matrix-metalloproteinase activity in a mouse model of cerebral ischemia using multispectral-optoacoustic-tomography
  136. Non-invasive detection of matrix-metalloproteinase activity in a mouse model of cerebral ischemia using multispectral optoacoustic tomography
  137. Quantification of amyloid deposits and oxygen extraction fraction in the brain with multispectral optoacoustic imaging in arcAbeta mouse model of Alzheimer's disease
  138. Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models
  139. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510
  140. Psychological and neural mechanisms of rotating leadership in teams: the impact of engagement and shared mental model
  141. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease
  142. Extracerebral Tissue Damage in the Intraluminal Filament Mouse Model of Middle Cerebral Artery Occlusion
  143. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies
  144. P2‐257: Radioligand Binding Assays for Comparison of TAU Pet Probes, PBB3 and T807, in Detection of TAU Pathologies in Alzheimer's Disease and PSP Brains, and Neurotoxic TAU Species in a Transgenic Mouse Model
  145. P4‐254: Characterization of regional binding of clinical amyloid tracers in autosomal dominant and sporadic Alzheimer's disease brains and their interactions with resveratrol
  146. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study
  147. O4‐02‐05: DIFFERENT TIME COURSE OF ASTROCYTOSIS AND AMYLOID DEPOSITION IN ALZHEIMER'S APPSWE TRANSGENICE MICE: A MULTI‐TRACER MICROPET STUDY
  148. 3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain
  149. O2–11–03: Astrocytosis precedes amyloid deposition in Alzheimer's Tg2576 APPswe transgenic mice: A multi‐tracer microPET imaging study
  150. IC‐P‐038: Astrocytosis precedes amyloid deposition in Alzheimer's disease Tg2576 APPswe transgenic mice: A multitracer microPET imaging study
  151. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
  152. Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients
  153. Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer's Disease Brain
  154. P2‐487: Alpha7 nicotinic receptor agonists interrupt the interaction between fibrillar amyloid and nicotinic receptor in Alzheimer's brain
  155. P4‐301: Evolution of fibrillar amyloid in relation to astro‐ and microgliosis and alterations in α7 nicotinic receptors in Alzheimer APPswe mice as studied with multi‐tracer concept
  156. P2‐329: Laminar distributions of fibrillar β‐amyloid and activated astrocytes in Alzheimer's disease autopsy brain: A quantitative autoradiography study
  157. P.1.002 Drug interaction between fibrillar amyloid β and alpha7 nicotinic receptor in Alzheimer brain